OBJECTIVE: Venous thromboembolism (VTE) is an uncommon, but potentially morbid, complication following foot and ankle fractures. Current standard is to not administer thromboprophylaxis to patients with such injuries. Nonetheless, patient and fracture factors might affect this risk/benefit consideration. The goal of this study was to determine what patients are most at risk. METHODS: The M53Ortho Pearldiver database was used to identify patients with fractures isolated to the foot and ankle that were treated non-operatively or operatively. Patients with pilon, other appendicular fractures remote from the foot and ankle, and other traumatic injuries were excluded. The 90-day occurrence of VTE was identified based on codes for deep vein thrombosis or pulmonary embolism. Characteristics of those patients who did and did not have VTEs were compared using chi-square analyses. Multivariate logistical regression was then performed to determined factors independently associated with VTE. Finally, timing of VTE relative to fracture was analyzed. RESULTS: A total of 298,886 patients with isolated foot or ankle fractures were identified, of which 1,661 (0.56%) had VTE in the 90 days following fracture. In terms of timing, 27.3% occurred in the first week, and 49.8% occurred in the first three weeks. Independent risk factors for VTE included (in decreasing order):prior VTE (odd ratio [OR] = 25.44), factor V Leiden (OR = 24.34), active cancer (OR = 1.84), specific fracture relative to metatarsal fracture (multiple fractures [OR: 1.51], ankle fracture [OR = 1.51], and calcaneus fracture [OR = 1.24]), surgical treatment (OR = 1.41), male sex (OR = 1.19), greater Elixhauser index (OR = 1.05), and increasing age (OR:1.05 per decade) (p<0.05 for each). CONCLUSIONS: The present study found that, although only 0.56% of isolated foot and ankle fractures had a VTE within ninety days. Defined risk factors, such as Factor V Leiden, prior VTE, surgical treatment, active cancer, specific fracture patterns, and surgical treatment significantly affected the odds of their occurrence.
OBJECTIVE: Venous thromboembolism (VTE) is an uncommon, but potentially morbid, complication following foot and ankle fractures. Current standard is to not administer thromboprophylaxis to patients with such injuries. Nonetheless, patient and fracture factors might affect this risk/benefit consideration. The goal of this study was to determine what patients are most at risk. METHODS: The M53Ortho Pearldiver database was used to identify patients with fractures isolated to the foot and ankle that were treated non-operatively or operatively. Patients with pilon, other appendicular fractures remote from the foot and ankle, and other traumatic injuries were excluded. The 90-day occurrence of VTE was identified based on codes for deep vein thrombosis or pulmonary embolism. Characteristics of those patients who did and did not have VTEs were compared using chi-square analyses. Multivariate logistical regression was then performed to determined factors independently associated with VTE. Finally, timing of VTE relative to fracture was analyzed. RESULTS: A total of 298,886 patients with isolated foot or ankle fractures were identified, of which 1,661 (0.56%) had VTE in the 90 days following fracture. In terms of timing, 27.3% occurred in the first week, and 49.8% occurred in the first three weeks. Independent risk factors for VTE included (in decreasing order):prior VTE (odd ratio [OR] = 25.44), factor V Leiden (OR = 24.34), active cancer (OR = 1.84), specific fracture relative to metatarsal fracture (multiple fractures [OR: 1.51], ankle fracture [OR = 1.51], and calcaneus fracture [OR = 1.24]), surgical treatment (OR = 1.41), male sex (OR = 1.19), greater Elixhauser index (OR = 1.05), and increasing age (OR:1.05 per decade) (p<0.05 for each). CONCLUSIONS: The present study found that, although only 0.56% of isolated foot and ankle fractures had a VTE within ninety days. Defined risk factors, such as Factor V Leiden, prior VTE, surgical treatment, active cancer, specific fracture patterns, and surgical treatment significantly affected the odds of their occurrence.
Authors: Nathaniel T Ondeck; Patawut Bovonratwet; Izuchukwu K Ibe; Daniel D Bohl; Ryan P McLynn; Jonathan J Cui; Michael R Baumgaertner; Jonathan N Grauer Journal: J Orthop Trauma Date: 2018-05 Impact factor: 2.512
Authors: M S Mizel; H T Temple; J D Michelson; R G Alvarez; T O Clanton; C C Frey; A P Gegenheimer; S R Hurwitz; L D Lutter; M G Mankey; R A Mann; R A Miller; E G Richardson; L C Schon; F M Thompson; M L Yodlowski Journal: Clin Orthop Relat Res Date: 1998-03 Impact factor: 4.176
Authors: Kevin T Huang; Matthew Hazzard; Steven Thomas; Gustavo Chagoya; Rand Wilcox Vanden Berg; Owoicho Adogwa; Carlos A Bagley; Robert Isaacs; Oren N Gottfried; Shivanand P Lad Journal: J Clin Neurosci Date: 2015-02-15 Impact factor: 1.961
Authors: Bengt I Eriksson; Ola E Dahl; Michael H Huo; Andreas A Kurth; Stefan Hantel; Karin Hermansson; Janet M Schnee; Richard J Friedman Journal: Thromb Haemost Date: 2011-01-12 Impact factor: 5.249
Authors: Nathaniel T Ondeck; Daniel D Bohl; Patawut Bovonratwet; Ryan P McLynn; Jonathan J Cui; Jonathan N Grauer Journal: J Arthroplasty Date: 2017-09-01 Impact factor: 4.757
Authors: Carlos B Mantilla; Terese T Horlocker; Darrell R Schroeder; Daniel J Berry; David L Brown Journal: Anesthesiology Date: 2003-09 Impact factor: 7.892
Authors: Banne Nemeth; Willem M Lijfering; Rob G H H Nelissen; Inger B Schipper; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter Journal: JAMA Netw Open Date: 2019-05-03